ABSTRACT
Evaluation of treatment response is an important parameter in the clinical oncology routine. For its power in predicting prognosis thorough providing metabolic information, positron emission tomography/computerized tomography (PET/CT) has gained a wide range of spectrum in the oncological imaging setting. Fluorodeoxyglucose (FDG) PET/CT is a problem solving tool especially in differentiating residual viable tumor and post therapeutical inflammatory changes. In this review, current information on the use of FDG PET/CT in the evaluation of treatment response in head and neck tumors, which ranks 6th in cancer death order, is discussed.
References
1American Cancer Society. Cancer Facts & Figures 2016. Am Cancer Soc Inc https://doi.org/10.1177/0300985809357753.
2Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.
3Lavertu P, Adelstein DJ, Saxton JP, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck 1997;19:559-566.
4Wong WL, Hussain K, Chevretton E, et al. Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose head and neck images. Am J Surg 1996;172:628-632.
5Barkley HT Jr, Fletcher GH, Jesse RH, Lindberg RD. Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx. Am J Surg 1972;124:462-467.
6Mehanna H, Wong WL, McConkey CC, et al. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med 2016;374:1444-1454.
7Therasse P, Arbuck SG. Eisenhauer EA, et al. New Guidelines to Evaluate the Response toTreatment in Solid Tumors. JNCI J Natl Cancer Inst 2000;92:205-216.
8Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122-150.
9O JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016;280:576-584.
10Kim JH. Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review. Oncotarget 2016;7:58105-58110.
11Katsuura T, Kitajima K, Fujiwara M, et al. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST. Ann Nucl Med 2018;32:453-462.
12Turgeon GA, Iravani A, Akhurst T, et al. What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria? J Nucl Med 2019;60:328-334.
13Sjövall J, Bitzén U, Kjellén E, Nilsson P, Wahlberg P, Brun E. Qualitative interpretation of PET scans using a Likert scale to assess neck node response to radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 2016;43:609-616.
14Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009;50:1257-1260.
15Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011;33:1675-1682.
16Marcus C, Ciarallo A, Tahari AK, et al. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. J Nucl Med 2014;55:1411-1416.
17Van den Wyngaert T, Helsen N, Carp L, et al. Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study. J Clin Oncol 2017;35:3458-3464.
18Aiken AH, Rath TJ, Anzai Y, et al. ACR Neck Imaging Reporting and Data Systems (NI-RADS): A White Paper of the ACR NI-RADS Committee. J Am Coll Radiol 2018;15:1097-1108.
19Zhong J, Sundersingh M, Dyker K, et al. Post-treatment FDG PET-CT in head and neck carcinoma: comparative analysis of 4 qualitative interpretative criteria in a large patient cohort. Sci Rep 2020;10:4086.
20Helsen N, Roothans D, Van Den Heuvel B, et al. 18F-FDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy. PLoS One 2017;12:e0182350.
21Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269.
22Zhou S, Rulach R, Hendry F, et al. Positron Emission Tomography-Computed Tomography Surveillance after (Chemo)Radiotherapy in Advanced Head and Neck Squamous Cell Cancer: Beyond the PET-NECK Protocol. Clin Oncol (R Coll Radiol) 2020;32:665-673.
